These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 14500583)

  • 41. The prognostic and predictive values of ECD-HER-2.
    Hait WN
    Clin Cancer Res; 2001 Sep; 7(9):2601-4. PubMed ID: 11555568
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy.
    Harris LN; Liotcheva V; Broadwater G; Ramirez MJ; Maimonis P; Anderson S; Everett T; Harpole D; Moore MB; Berry DA; Rizzeri D; Vredenburgh JJ; Bentley RC
    J Clin Oncol; 2001 Mar; 19(6):1698-706. PubMed ID: 11250999
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
    Svoboda M; Grell P; Simícková M; Fabian P; Petráková K; Palácová M; Macková D; Trojanec R; Hajdúch M; Pavlík T; Nenutil R; Vyzula R
    Klin Onkol; 2008; 21(6):348-58. PubMed ID: 19382598
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predicting the clinical course of breast cancer patients undergoing trastuzumab-based therapy: an outlook.
    Hudelist G; Köstler W; Czerwenka K; Kubista E; Singer CF
    Methods Find Exp Clin Pharmacol; 2004 Apr; 26(3):201-10. PubMed ID: 15148526
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients.
    Hoopmann M; Sachse K; Valter MM; Becker M; Neumann R; Ortmann M; Göhring UJ; Thomas A; Mallmann P; Schöndorf T
    Eur J Cancer Care (Engl); 2010 Nov; 19(6):809-15. PubMed ID: 20105224
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
    Colomer R; Llombart-Cussac A; Lloveras B; Ramos M; Mayordomo JI; Fernández R; Tusquets I; Gil M; Barnadas A; Constenla M; Gilabert M; Alba E
    Cancer; 2007 Nov; 110(10):2178-85. PubMed ID: 17926331
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
    Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H
    Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Challenges in the clinical utility of the serum test for HER2 ECD.
    Lam L; McAndrew N; Yee M; Fu T; Tchou JC; Zhang H
    Biochim Biophys Acta; 2012 Aug; 1826(1):199-208. PubMed ID: 22521738
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients.
    Bethune-Volters A; Labroquere M; Guepratte S; Hacene K; Neumann R; Carney W; Pichon MF
    Anticancer Res; 2004; 24(2C):1083-9. PubMed ID: 15154627
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours.
    Pallud C; Guinebretiere JM; Guepratte S; Hacene K; Neumann R; Carney W; Pichon MF
    Anticancer Res; 2005; 25(2B):1433-40. PubMed ID: 15865102
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Automated assay for HER-2/neu in serum.
    Payne RC; Allard JW; Anderson-Mauser L; Humphreys JD; Tenney DY; Morris DL
    Clin Chem; 2000 Feb; 46(2):175-82. PubMed ID: 10657373
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
    Ali SM; Carney WP; Esteva FJ; Fornier M; Harris L; Köstler WJ; Lotz JP; Luftner D; Pichon MF; Lipton A;
    Cancer; 2008 Sep; 113(6):1294-301. PubMed ID: 18661530
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
    Hudelist G; Köstler WJ; Czerwenka K; Kubista E; Attems J; Müller R; Gschwantler-Kaulich D; Manavi M; Huber I; Hoschützky H; Zielinski CC; Singer CF
    Int J Cancer; 2006 Mar; 118(5):1126-34. PubMed ID: 16161043
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: a systematic review and meta-analysis.
    Zhang Z; Li C; Fan H; Xiang Q; Xu L; Liu Q; Zhou S; Xie Q; Chen S; Mu G; Cui Y
    Breast Cancer Res Treat; 2018 Dec; 172(3):513-521. PubMed ID: 30159787
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer.
    Abu-Khalaf MM; Harris L
    Breast Cancer Res Treat; 2009 Apr; 114(3):513-5. PubMed ID: 18677560
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer.
    Cook GB; Neaman IE; Goldblatt JL; Cambetas DR; Hussain M; Lüftner D; Yeung KK; Chan DW; Schwartz MK; Allard WJ
    Anticancer Res; 2001; 21(2B):1465-70. PubMed ID: 11396233
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
    Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ
    J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V; Witzel I; Pantel K; Krenkel S; Lück HJ; Neumann R; Keller T; Dittmer J; Jänicke F; Thomssen C
    Anticancer Res; 2006; 26(2B):1479-87. PubMed ID: 16619561
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.
    Vazquez-Martin A; Fernandez-Real JM; Oliveras-Ferraros C; Navarrete JM; Martin-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2009 Dec; 35(6):1369-76. PubMed ID: 19885560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.